1. 調査手法および対象範囲
1.1. 調査手法
1.2. 調査目的およびレポートの対象範囲
2. 定義および概要
3. エグゼクティブサマリー
3.1. 製品種類別抜粋
3.2. 用途別抜粋
3.3. 販売チャネル別抜粋
3.4. 地域別抜粋
4. ダイナミクス
4.1. 影響因子
4.1.1. 推進要因
4.1.1.1. 慢性疾患の増加
4.1.1.2. XX
4.2. 抑制要因
4.2.1. 治療法の採用を制限する要因
4.3. 機会
4.3.1. 影響分析
5. 業界分析
5.1. ポーターのファイブフォース分析
5.2. サプライチェーン分析
5.3. 価格分析
5.4. 規制分析
6. 製品種類別
6.1. はじめに
6.1.1. 市場規模分析および前年比成長率（%）：製品種類別
6.1.2. 市場魅力度指数：製品種類別
6.2. ソフトウェア*
6.2.1. はじめに
6.2.2. 市場規模分析および前年比成長率分析（％）
6.3. デバイス
6.4. その他
7. 用途別
7.1. はじめに
7.1.1. 市場規模分析および前年比成長率分析（％）、用途別
7.1.2. 用途別市場魅力度指数
7.2. 糖尿病*
7.2.1. はじめに
7.2.2. 市場規模分析および前年比成長率分析（％）
7.3. 肥満症
7.4. 循環器疾患（CVD
7.5. 中枢神経系（CNS）疾患
7.6. 呼吸器疾患
7.7. 禁煙
7.8. 消化器疾患（GID）
7.9. その他
8. 販売チャネル別
8.1. はじめに
8.1.1. 市場規模分析および前年比成長率分析（％）、販売チャネル別
8.1.2. 市場魅力度指数、販売チャネル別
8.2. 企業間取引（B2B）*
8.2.1. はじめに
8.2.2. 市場規模分析および前年比成長率分析（％）
8.3. 企業と消費者間取引（B2C）
9. 地域別
9.1. はじめに
9.1.1. 地域別市場規模分析および前年比成長率分析（％）
9.1.2. 市場魅力度指数、地域別
9.2. 北米
9.2.1. はじめに
9.2.2. 主な地域特有の動向
9.2.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.2.4. 市場規模分析および前年比成長率分析（％）、用途別
9.2.5. 販売チャネル別市場規模推移および前年比成長率（％）
9.2.6. 国別市場規模推移および前年比成長率（％）
9.2.6.1. 米国
9.2.6.2. カナダ
9.2.6.3. メキシコ
9.3. ヨーロッパ
9.3.1. はじめに
9.3.2. 主要地域別の動向
9.3.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.3.4. 市場規模分析および前年比成長率分析（％）、用途別
9.3.5. 市場規模分析および前年比成長率分析（％）、販売チャネル別
9.3.6. 市場規模分析および前年比成長率分析（％）、国別
9.3.6.1. ドイツ
9.3.6.2. 英国
9.3.6.3. フランス
9.3.6.4. スペイン
9.3.6.5. イタリア
9.3.6.6. ヨーロッパのその他地域
9.4. 南アメリカ
9.4.1. はじめに
9.4.2. 主な地域特有の動向
9.4.3. 製品種類別市場規模分析および前年比成長率（％）
9.4.4. 用途別市場規模分析および前年比成長率（％）
9.4.5. 販売チャネル別市場規模推移および前年比成長率（％）
9.4.6. 国別市場規模推移および前年比成長率（％）
9.4.6.1. ブラジル
9.4.6.2. アルゼンチン
9.4.6.3. 南米その他
9.5. アジア太平洋
9.5.1. はじめに
9.5.2. 主要地域別の動向
9.5.3. 市場規模分析および前年比成長率分析（％）、製品種類別
9.5.4. 市場規模分析および前年比成長率分析（％）、用途別
9.5.5. 市場規模分析および前年比成長率分析（％）、販売チャネル別
9.5.6. 国別の市場規模分析および前年比成長率分析（％）
9.5.6.1. 中国
9.5.6.2. インド
9.5.6.3. 日本
9.5.6.4. 韓国
9.5.6.5. アジア太平洋地域その他
9.6. 中東およびアフリカ
9.6.1. はじめに
9.6.2. 主要地域別の動向
9.6.3. 製品種類別市場規模分析および前年比成長率（％）
9.6.4. 用途別市場規模分析および前年比成長率（％）
9.6.5. 販売チャネル別市場規模分析および前年比成長率（％）
10. 競合状況
10.1. 競合シナリオ
10.2. 市場ポジショニング/シェア分析
10.3. 合併・買収分析
11. 企業プロフィール
Teladoc Health
2Morrow Inc
Omada Health, Inc
Resmed Inc
Voluntis, Inc
Kaia Health
Biofourmis
Click Therapeutics, Inc
WelldocのBlueStar
Lark Technologies, Inc
リストは網羅的なものではありません。
13. 付録
13.1 当社およびサービスについて
13.2 お問い合わせ
The global digital therapeutics market reached US$ 5.7 billion in 2023 and is expected to reach US$ 27.3 billion by 2031, growing at a CAGR of 21.6% during the forecast period 2024-2031.
Digital Therapeutics (DTx) is a patient-facing software application that aids in treating, preventing, or managing diseases. It is evidence-based and uses software for therapeutic intervention. Digital therapeutics allows simultaneous patient assistance and monitoring with live telemedicine sessions. Many chronic illness patients can access interventions from the comfort of their homes through mobile apps or web platforms.
Market Dynamics: Drivers & Restraints
Rise in the Prevalence of Chronic Diseases
The global digital therapeutics market is growing due to several factors such as the rise in the prevalence of chronic diseases, rising demands for digital therapeutics due to their advantages, such as induce behavioral change, user-friendliness, patient convenience, and improved drug compliance and novel digital therapeutics technological advances.
As chronic conditions like diabetes, hypertension, and obesity become more common, there is a growing demand for effective, long-term solutions beyond traditional pharmaceuticals. For instance, according to Mayo Clinic 2023, the transition between infectious and noncommunicable diseases began in the early 1900s due to improved public health. As individuals live longer, chronic disease prevalence and cost continue to rise, with the estimated cost reaching $47 trillion by 2030. Individual lifestyle, behaviors, and community factors significantly influence the development and management of chronic diseases.
Hence, the rising prevalence of chronic diseases due to aging populations and lifestyle factors necessitate effective management solutions digital therapeutics offers innovative, cost-efficient tools for disease prevention and management, scalability, and personalization, crucial in tackling global healthcare challenges.
Limiting the Adoption of Therapeutics
The market is hindered by several factors in the early phase stage of development some of them are like, limiting the adoption, high cost of digital therapeutics, the patient data privacy concerns and unstable payment models could hurt the market.
This market represents an emerging field of software and device-driven based products intended to prevent, manage or treat medical conditions. However, increasing issues related to cybersecurity are a major concern limiting the adoption of therapeutics. Patients are concerned about the risks and vulnerabilities in protecting their medical data. Certain risks and cyberattacks are responsible for the restrained adoption of these products in the forecast period.
For instance, in September 2022, the risk of cyberattacks on digital therapeutics apps increased as compared to previous years. The cyberattacks are due to the increased availability of more users and the rise in patient health information.
Segment Analysis
The global digital therapeutics market is segmented based on product type, application, sales channel, and region.
Product Type:
Softwares segment is expected to dominate the digital therapeutics market share
The softwares segment holds a major portion of the digital therapeutics market share and is expected to continue to hold a significant portion of the digital therapeutics market share during the forecast period.
The digital therapeutics market is segmented based on the product type as software, devices, and others. The software segment accounts for the highest market share due to the increasing demand for software to reduce healthcare costs worldwide. The software also provides regular online assistance from certified doctors. The market is dominated by several digital therapeutics software that helps the patients maintain their proper diet, track health data, and daily physical activities.
For instance, in June 2023 Digital Therapeutics Alliance (DTA) is announcing the launch of the Policymaker & Payor DTx Evaluation Toolkit, a comprehensive set of resources to enable global healthcare and digital technology leaders to broaden the understanding, adoption, and integration of clinically evaluated digital therapeutics (DTx) into healthcare.
Moreover, in January 2023 Curebase, a company committed to democratizing access to clinical trials, announced the release of its integrated software and services package for digital therapeutics (DTx) trials that accelerates enrollment and allows sponsors to launch their studies faster.
Diabetes segment is the fastest-growing segment in the digital therapeutics market share
The diabetes segment is the fastest-growing segment in the digital therapeutics market share and is expected to hold the market share over the forecast period.
Diabetes is a key chronic illness within the global digital therapeutics market, as many digital health solutions are aimed at addressing the problem of chronic diseases. Digital therapeutics such as mobile applications, wearable technology, and web-based systems are used to monitor blood glucose levels, compliance with medication, and lifestyle changes – diet and physical activity – thereby facilitating personalised interventions for diabetes management.
The segment is about to grow during the forecast period owing to the factors like, advancements in artificial intelligence, machine learning, and data analytics to provide real-time insights, personalized feedback, and predictive health management. Regulatory approvals for digital therapeutics targeting diabetes and increasing payer coverage further strengthen the segment's growth.
For instance, in January 2024, Eli Lilly has launched LillyDirect, a digital healthcare platform for US patients with obesity, migraine, and diabetes. The platform provides disease management resources, tailored support, and direct home delivery of select Lilly medicines through third-party pharmacy dispensing services. The aim is to simplify the patient experience and improve outcomes by offering more choices in healthcare access, including a convenient home delivery option for prescribed Lilly medicines. The company's chair and CEO, David A. Ricks, praised Lilly's approach.
Moreover, in October 2023, Better Therapeutics has launched its AspyreRx digital diabetes therapeutic app, becoming the first cognitive behavioral therapy (CBT) to receive FDA authorization for treating type 2 diabetes. The prescription digital therapeutic, formerly BT-001, provides CBT to patients aged 18 and older with type 2 diabetes.
Geographical Analysis
North America is expected to hold a significant position in the digital therapeutics market share
North America holds a substantial position in the digital therapeutics market and is expected to hold most of the market share due to the patient-centric healthcare approach for patient wellness, growing improvement in the reimbursement structure for digital therapeutics and others.
Moreover, an increasing number of collaborations and agreements amongst the key players to focus on the research and development of these products is expected to increase the introduction of these devices in the region.
For instance, in October 2024, The Center for Technology and Behavioral Health (CTBH) at the Geisel School of Medicine at Dartmouth is partnering with Boehringer Ingelheim to develop digital therapeutics for serious mental illness. The collaboration will use academic research and healthcare industry strengths to create tools to tackle the global mental health crisis. CTBH's founding director, Lisa Marsch, emphasizes the importance of bringing the best science to create effective tools and ensuring they have a real impact on people's lives globally.
Moreover, in October 2024, Click Therapeutics, Inc a leader in digital therapeutics as prescription medical treatments, announced the launch of Software-Enhanced Drug therapies, part of a new product offering called Click SE. With this launch, Click Therapeutics is creating a novel category of prescription digital therapeutic products in view of the increasing engagement in the U.S. Food and Drug Administration (FDA) draft guidance on the Prescription Drug-Use Related Software (PDURS). Hence, the above-mentioned factors help the North America region to grow during the forecast period.
Europe is growing at the fastest pace in the digital therapeutics market
Europe holds the fastest pace in the digital therapeutics market and is expected to hold most of the market share due to the driving forces for the Europe region, which poses a great potential for the global digital therapeutics market. The developed healthcare system and high level of integration of digital health in this region has made it possible to employ digital therapeutics in the treatment of many diseases such as diabetes, cardiovascular and mental disorders.
Moreover, funding from companies, supportive policies adopted by the governments, such as reimbursement of costs associated with the use of digital health solutions, as well as spending on healthcare digitization, have additional boosted the market. Besides, the combination of high incidence of chronic illnesses in Europe, which is accompanied by an older population, has created a possible use of remote patient monitoring systems and targeted health care services, which has contributed further to the market.
For instance, in August 2024, the Innovate UK recently declared the funding of 24 projects focused on the development of immersive digital mental health therapeutics. This award is part of Innovate UK’s £20 Billion Mindset initiative that is aiding the expansion of immersive digital mental illness solutions within the UK. In addition to their support towards marketplaces, which focus on the rehabilitation of patients doling out therapeutic interventions, Mindset is establishing a strong ecosystem to help commercialize these innovations.
Competitive Landscape
The major global players in the digital therapeutics market include Teladoc Health, 2Morrow Inc, Omada Health, Inc, Resmed Inc , Voluntis, Inc, Kaia Health, Biofourmis, Click Therapeutics, Inc, Welldoc's BlueStar, Lark Technologies, Inc among others.
Emerging Players
The emerging players in the digital therapeutics market include Happify Health, Cognoa, Propeller Health, Akili Interactive Labs and among others.
Key Developments
• In August 2024, Otsuka Precision Health and Click Therapeutics have launched Rejoyn, a prescription digital therapeutic for treating major depressive disorder symptoms which is cleared by the FDA in March 2024, Rejoyn is used as an adjunct to clinician-managed outpatient care for adult patients aged 22 and older on antidepressant medication.
• In January 2023, Lupin Digital Health has launched its digital therapeutics solution, LYFE, which is an evidence-based heart care program designed by leading Indian cardiologists. LYFE helps patients improve their heart health through doctor-connected online and offline modules, FDA and CE-approved wearable devices that record vital parameters, notify caregivers and doctors about off-range vitals and emergencies, and offer medication reminders and 24x7 emergency and ambulance assistance.
Why Purchase the Report?
• To visualize the global digital therapeutics market segmentation based on product type, application, sales channel and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of the digital therapeutics market with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.
The global digital therapeutics market report would provide approximately 70 tables, 65 figures, and 184 pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by Sales Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rise in the Prevalence of Chronic Diseases
4.1.1.2. XX
4.2. Restraints
4.2.1. Limiting The Adoption of Therapeutics
4.3. Opportunity
4.3.1. Impact Analysis
5. Industry Analysis
5.1. Porter’s Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Software*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Devices
6.4. Others
7. By Application
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
7.1.2. Market Attractiveness Index, By Application
7.2. Diabetes*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Obesity
7.4. Cardiovascular Diseases (CVD)
7.5. Central Nervous System (CNS) Diseases
7.6. Respiratory Diseases
7.7. Smoking Cessation
7.8. Gastrointestinal Disorders (GID)
7.9. Others
8. By Sales Channel
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
8.1.2. Market Attractiveness Index, By Sales Channel
8.2. Business to Business (B2B) *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Business to Consumer (B2C)
9. By Region
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
9.1.2. Market Attractiveness Index, By Region
9.2. North America
9.2.1. Introduction
9.2.2. Key Region-Specific Dynamics
9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.2.6.1. U.S.
9.2.6.2. Canada
9.2.6.3. Mexico
9.3. Europe
9.3.1. Introduction
9.3.2. Key Region-Specific Dynamics
9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.3.6.1. Germany
9.3.6.2. U.K.
9.3.6.3. France
9.3.6.4. Spain
9.3.6.5. Italy
9.3.6.6. Rest of Europe
9.4. South America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. Brazil
9.4.6.2. Argentina
9.4.6.3. Rest of South America
9.5. Asia-Pacific
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. China
9.5.6.2. India
9.5.6.3. Japan
9.5.6.4. South Korea
9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Sales Channel
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Teladoc Health*
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Financial Overview
11.1.4. Key Developments
11.2. 2Morrow Inc
11.3. Omada Health, Inc.
11.4. Resmed Inc
11.5. Voluntis, Inc
11.6. Kaia Health
11.7. Biofourmis
11.8. Click Therapeutics, Inc
11.9. Welldoc's BlueStar
11.10. Lark Technologies, Inc
LIST NOT EXHAUSTIVE
13. Appendix
13.1 About Us and Services
13.2 Contact Us
*** デジタル治療の世界市場に関するよくある質問(FAQ) ***
・デジタル治療の世界市場規模は？
→DataM Intelligence社は2023年のデジタル治療の世界市場規模を57億米ドルと推定しています。
・デジタル治療の世界市場予測は？
→DataM Intelligence社は2031年のデジタル治療の世界市場規模を273億米ドルと予測しています。
・デジタル治療市場の成長率は？
→DataM Intelligence社はデジタル治療の世界市場が2024年～2031年に年平均21.6%成長すると展望しています。
・世界のデジタル治療市場における主要プレイヤーは？
→「Teladoc Health、2Morrow Inc、Omada Health, Inc、Resmed Inc、Voluntis, Inc、Kaia Health、Biofourmis、Click Therapeutics, Inc、WelldocのBlueStar、Lark Technologies, Incなど ...」をデジタル治療市場のグローバル主要プレイヤーとして判断しています。
※上記FAQの市場規模、市場予測、成長率、主要企業に関する情報は本レポートの概要を作成した時点での情報であり、最終レポートの情報と少し異なる場合があります。
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
